Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

September 4, 2020 12:14 AM UTC

The failure of Akebia’s vadadustat on a Phase III safety endpoint in a subset of chronic kidney disease patients won’t stop the company from submitting the molecule to regulators. But the readout surprised investors and destroyed more than $1 billion in the company’s market cap, and it could widen a commercial avenue for a rival drug from Fibrogen.

Akebia Therapeutics Inc. (NASDAQ:AKBA) said Thursday that vadadustat missed the primary safety endpoint in the Phase III PRO2TECT program, which evaluated the oral HIF-PH inhibitor to treat anemia in non-dialysis-dependent CKD patients. Vadadustat did not show non-inferiority to erythropoietin-stimulating agent Aranesp darbepoetin alfa as measured by time to first occurrence of major adverse cardiovascular events, or MACE (non-inferiority margin=1.25; HR=1.17; 95% CI: 1.01, 1.36)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article